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Available online 26 August 2016From2006 to 2011, Roslin Cells Ltd derived 17 human embryonic stem cells (hESC)while developing (RCM1, RC-
2 to -8, -10) and implementing (RC-9, -11 to -17) quality assured standards of operation in a facility operating in
compliance with European Union (EU) directives and United Kingdom (UK) licensure for procurement, process-
ing and storage of human cells as sourcematerial for clinical application, and targeted to complywith an EUGood
Manufacturing Practice speciﬁcation.Herewe describe the evolution and speciﬁcation of the facility, its operation
and outputs, complementing hESC resource details communicated in Stem Cell Research Lab Resources.
© 2016 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Since theﬁrst report of pluripotent hESC isolation in 1998 (Thomson
et al., 1998) there has been an aspiration to use these cells in regenera-
tive medicine to repair disease and damaged tissue. This has driven
efforts towards establishing benchmarks for the ﬁeld (Andrews et al.,
2005; Andrews et al., 2015), development of reagents, methods and
tools to reduce or obviate the risk of transmitting adventitious
pathogens (De Sousa, 2013) and the application of evolving standards
of quality assurance (QA) and Good Manufacturing Practice (GMP) to
satisfy regulatory aims of product safety, quality and efﬁcacy
(De Sousa et al., 2006). There have been at least two reports of “clinical.2016.02.036, http://dx.doi.org/
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.2016.04.021, http://dx.doi.org/
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.2016.04.019, http://dx.doi.org/
.2016.02.034, http://dx.doi.org/
Edinburgh Bio-Quarter, 9 Little
).
pen access article under the CC BY-Ngrade” hESC lines compliant with US Food and Drug Administration
(Crook et al., 2007; Tannenbaum et al., 2012) and numerous cell lines
deposited in stem cell repositories such as the UK stem cell bank
(UKSCB) designated as suitable for clinical use based on bank assess-
ment of depositor information (go to: http://www.nibsc.org/science_
and_research/advanced_therapies/uk_stem_cell_bank/cell_lines/
approved_by_the_bank.aspx). Ultimately whether a cell line qualiﬁes
as source material for a cell therapy product (CTP) depends on its
acceptance by regulatory authorities when authorisation for clinical
evaluation is sought. Since cellular therapy is a relatively new science,
the requirements of the regulators continue to evolve as their under-
standing of the issues surrounding this type of treatment has advanced.
Newguidance is being generated fairly rapidly, and the suitability of any
cell linewill be judged as andwhen an application is made for licensure
to a particular regulatory body.
The ﬁrst US FDA authorisation of an hESC derived cell product in a
clinical phase 1/2a safety/efﬁcacy (i.e. an oligodendroglial progenitor
for spinal cord repair sponsored ﬁrst by the Geron Corporation and
then Asterias Biotherapeutics, http://www.nature.com/news/funding-
windfall-rescues-abandoned-stem-cell-trial-1.15350) was founded on
hESC source material ﬁrst isolated using research grade reagents and
laboratory conditions and subsequently transitioned into current Good
Tissue Practice (GTP) and GMP. More recently, there have been several
independent authorisations in the US and the EU of hESC based cellC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
380 P.A. De Sousa et al. / Stem Cell Research 17 (2016) 379–390therapy products for the treatment of variant forms of age-related
macular degeneration with comparable or improved provenance
(www.clinicaltrials.gov). Assessment of risk and retrospective testing,
such as for adventitious pathogens, can help qualify source cell material
and reagents not originally isolated under standards suitable for clinical
use. However, negative results from these tests are always qualiﬁed by
their limits of sensitivity. If available, source material qualiﬁed as
suitable for clinical use from the onset of its derivation constitutes a
preferable starting point for next generation advanced cell therapies.
This ismore likely towithstand elevations in the expectations of regula-
tory standards than non-GMP grade alternatives whose use requires
more robust risk assessment.
In the EU, market authorization of Advanced Therapy Medicinal
Products (ATMPs) encompassing gene, somatic and tissue engineered
therapies is governed today by the European Medicines Agency (EMA)
via a compulsory centralized process valid in all EU countries as well
as some European Economic Area countries (Iceland, Norway and
Liechtenstein). Governance is informed by European Commission (EC)
directives (see Table 1) that are transacted into regulations and laws
in EU member states that retain freedom to set more stringent stan-
dards or set policy regarding use of speciﬁc cell types. In the course of
the effort described herein and at time of writing, the UK has developed
and empowered governing bodies to regulate the procurement, pro-
cessing and use of human embryo derived cells for clinical applications
which aligned with EU commission directives and EMA requirements,
namely; i) The Human Fertilisation and Embryology Authority (HFEA)
for the procurement, processing, storage and use of human gametes
and embryos. HFEA licensure requires that hESC lines are deposited in
the UKSCB, whose terms of deposition dictate agreement to make the
line available for research approved by the Medical Research Council.
ii) The Human Tissue Authority (HTA), for the procurement, processing
and storage of all human cells for human application, and iii) the
Medicines and Healthcare Products Regulatory Agency (MHRA), as
regards inspection and authorization of sites of production and applica-
tion of medicines and devices such as may use cells sourced as starting
materials. EU and UK authorities beneﬁt from guidance provided by
advisory committees such as for example the EMA Committee on
Advanced Therapies (CAT) and UK Department of Health Advisory
Committee on Safety of Blood Tissues and Organs (SaBTO). By compar-
ison at time of writing in the US cell manufacturing processes involvingTable 1
Speciﬁcation of quality assured hESC RC9, 11–17 as source material for clinical application in relat
pean Commission; QSS – Quality and Safety Standards; GLP –Good Laboratory Practice; GCP – G
Product.
Phase (standard) Directive/Regulation Title
Procurement (QSS) 2004/23/EC Quality and safety standards for the donatio
distribution of human tissues and cellsProcessing/storage
(QSS)
2004/23/EC
2006/17/EC Technical requirements for the donation, pr
human tissues and cells
2006/86/EC Traceability requirements, notiﬁcation of ser
events and technical requirements for codin
storage and distribution of human tissues an
2012/39/EU Amending 2006/17/EC as regards certain tec
testing of human tissues and cells
Clinical manufacture
(GMP)
2003/94/EC Good manufacturing practice in respect of m
use and investigational medicinal products f
EudraLex Vol 4 Guidance for good manufacturing practice fo
human and veterinary use
Production related
issues
2009/120/EC Amendment to 2001/83/EC relating to medi
as regards advanced therapy medicinal prod
EC 1394/2007 Regulation on advanced therapy medicinal p
2001/83/EC and regulation (EC) No. 726/200
EC 726/2004 Regulation laying down community procedu
supervision of medicinal products for huma
European Medicines Agencysubstantial manipulation are deemed to be a subclass of somatic cellular
therapies and regulated as biologics under section 351 of the Public
Health Act and associated codes of federal regulation (see Table 2). In
the US the FDA ofﬁce of Cellular Tissue and Gene Therapies (OCTGT)
and Centre for Biologics Evaluation and Research (CBER) authorizes/
regulates investigational new drug (IND) applications for licensure of
cellular and gene therapy products and associated devices, also with
advisory committee input. Both jurisdictions emphasize the implemen-
tation of the highest possible quality assured practice for procurement,
processing, storage and distribution, for which licensure and accredita-
tion provide important warrants through associated inspection and
audits.
Following fromour prior research to derive newhESC lines under in-
creasingly deﬁned culture conditions (Fletcher et al., 2006) we sought
to establish a facility withinwhich our experience and evolving practice
and reagents could be implemented to a GMP and professionally
accredited standard. Here we describe the concurrent evolution and
speciﬁcation of the resulting facility established in the form of a not-
for-proﬁt company Roslin Cells Ltd, whose operation from January
2006 to November 2011, yielded seventeen new hESC lines. These
were established in the course of developing and implementing QA
and GMP standards in a UK authority licensed and ISO:9001 accredited
facility. In so doing we believe that we have generated 8 hESC lines
which comply with the current EU and US guidance and regulation
governing their suitability to be considered as source material for
human application. Information provided herein complements further
details of resource methodology and hESC line characterisation
published in Stem Cell Research Lab Resource format (De Sousa et al.,
2009; De Sousa et al., 2016a, 2016b, 2016c, 2016d, 2016e, 2016f,
2016g, 2016h, 2016i, 2016j, 2016k, 2016l, 2016m, 2016n, 2016o,
2016p, 2016q). Cell line history ﬁles with associated protocols and
records are available for auditing by prospective licensors and regulato-
ry authorities under conﬁdentiality agreement.
2. Methods
2.1. Overview of operational establishment
Roslin Cells (RC) Ltd was founded in October 2005 as a corporate
vehicle to integrate requisite hESC science and technology, GMP cellion to EU Directives/Regulations governing advanced therapy medicinal products. EC – Euro-
ood Clinical Practice; GMP – Good Manufacturing Practice; IMP – Investigational Medicinal
Compliance (□) and/or comment (•)
n, procurement, storage and ✓ HFEA & HTA license
✓ Quality Management System.
✓ Independent audits
✓ History File
ocurement and testing of
ious adverse reactions and
g, processing, preservation,
d cells
hnical requirements for the ✓ HTLV1 testing high risk donors
edicinal products for human
or human use.
• RC9, 11–17 seed banks established under license
from HFEA/HTA for production of source material
for human application.
• Targeting EU GMP speciﬁcation.
r medicinal products for
cinal products for human use
ucts
• Traceability compliant with 2004/23/EC
• Information on starting materials and developmental
process as well as products
roducts, amending directive
4
• Donation, procurement, processing, storage and
distribution compliant with 2004/23/EC
res for the authorisation and
n use and establishing the
• Cross-reference to MAA directive (2001/83/EC),
amendments and regulation
Table 2
Speciﬁcation of quality assured RC9, 11–17 hESC lines as source material for human application in relation to US FDA regulations. GLP – Good Laboratory Practice; GCP – Good Clinical
Practice; GMP – Good Manufacturing Practice; GTP – Good Tissue Practice. CFR – Code of Federal Regulation; USC – United States Code (Regulation); IND – Investigational New Drug.
Process (standard) Directive/Regulation Title Compliance ( ̈□) or comment (•)
Procurement (GTP) 21CFR1271 Human cells, tissues, and cellular
tissue-based products
✓ Deﬁne, document, implement, review, revise, trace procedures for traceably anonymous
testing, screening, determination of donor eligibility
✓ Donor free from risk factors, clinical evidence of, infection of communicable agents using
certiﬁed tests where available.
✓ Medical history assessment of risk of transmissable spongiform encephalopathy
• Our donors - screened for HIV1/2, HepB/C. risk assessed and if warranted tested for
communicable diseases of genitourinary tract.
Process/storage
(GTP)
21CFR1271 ✓ Facility environmental control, maintenance, monitoring and records
✓ Equipment procedures, calibration, inspection, records, & assurance to prevent
introduction, transmission, spread of communicable diseases
✓ Supplies and reagents veriﬁed to meet speciﬁcations designed to prevent circumstances
that increase risk of communicable diseases
✓ Recovery in a manner that does not introduce, transmit or spread communicable
diseases
✓ Processing and process controls – veriﬁcation and validation of any change in process
✓ Storage and labeling – controls to prevent mix ups, contamination, cross-contamination
and assure traceability, and means for corrective actions
✓ Receipt/predistribution shipment, and distribution - controls to prevent transmission of
communicable disease and safeguard product integrity
✓ Third party contract agreements
✓ Quality programme deﬁning, documenting, implementing, reviewing, revising, auditing
standard operational procedures
✓ Personnel suitability, training and competence
✓ Complaint ﬁle – establish and maintain procedures for review, evaluation and
documentations of complaints
✓ Reporting – deviations, adverse events, preventative and corrective actions.
✓ Inspection ready and responsive
21CFR1270 (Pre
May 2005)
Human tissue intended for
transplantation
✓ Procedures for infectious disease testing, reviewing, assessing medical records;
designating and quarantining tissue, prevention of infectious diseases contamination
or cross-contamination.
✓ Records – indelible and legible, identifying person performing work, documentation
of tissue receipt, processing, storage and disposal
✓ Inspection ready and responsive
✓ Retention, recall, destruction competent
42USC264 Regulations to control communicable
diseases
• Not applicable – pertaining to apprehension, detection, or conditional release of
individuals to prevent introduction, transmission or spread of communicable diseases
from foreign countries into or within the United States
Clinical manufacture
(GMP)
21CFR210 Current GMP in manufacturing,
processing, packing or holding of
drugs; general
• Targeting EU GMP speciﬁcation.
21CFR211 Current GMP for ﬁnished
pharmaceuticals
Non-clinical studies
(GLP)
21CFR58 GLP for nonclinical laboratory studies ✓ Afﬁrmed by BSI9001:2008 accredited.
21CFR610 General Biological Products Standards ✓ We have established equivalence of methods, potency, sterility, mycoplasma,
purity, identity, constituent materials, speciﬁcs of culture and storage, tests
implemented to screen for communicable diseases.
Clinical trials (GCP) 21CFR312 Investigational new drug (IND)
application
• Not applicable. IND not applied for as product constitutes source material
21CFR50 Protection of human subjects • Legally effective informed consent in understandable language containing basic
elements of consent, without exculpatory language or waiving donor's legal rights, or
appearing to release investigator, sponsor, its institution or its agents from liability for
negligence.
21CFR54 Financial disclosure by clinical
investigators
✓ Embryos donated to not-for-proﬁt organisation.
21CFR56 Institutional review boards • Institutional and health service for procurement of primary tissue
21CFR11 Electronic records and signatures • Provided by Quality Management System
Biological license
application - BLA
21CFR600 Biologics • Not applied for, but requirements consistent with speciﬁcation of HTA license, Quality
Management System and BSI9001:2008 accreditation.
21CFR601 Licensing • As for 21CFR600
43 USC 262 Regulations of Biological products • As for 21CFR600
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stakeholders in Scotland for the common goal of establishing resources
and capability to facilitate the translation of hESC research into new
regenerative medicines (Fig. 1). Founding institutions included the
University of Edinburgh and Roslin Foundation (Stakeholders), and
the Scottish National Blood Transfusion Service (SNBTS) and Scottish
Enterprise (SE) (Observers), providing contributions in kind and
funding (SE). This formed part of a greater strategic commitment of
these institutions in support of the advancement of regenerativemedicine ultimately including the construction of the University of
Edinburgh Scottish Centre for Regenerative Medicine (SCRM; https://
en.wikipedia.org/wiki/Scottish_Centre_for_Regenerative_Medicine).
The facilities, operation and cell lines described herein were established
in purpose built facilities constructed and operating at the Roslin
Biocentre from 2005 to 2011 (Fig. 2). After this time the operation
was relocated into an expanded (1000m2) GMP cellular therapy facility
constructed within the SCRM, which at the time of writing remains the
principal storage site of banked hESC lines.
Fig. 1. Overview of intra and inter-organisational relationships in the establishment of a
GMP hESC production capacity. The founding institutions of Roslin Cells included the
University of Edinburgh (UEDIN), Roslin Foundation (RF), the Scottish National Blood
Transfusion Service (SNBTS) and Scottish Enterprise (SE), which assumed legal status as
stakeholders (UEDIN, RF) and observers (SNBTS, SE) in accordance with institutional
limitations precluding conﬂict of interests. The organisation's executive team and
staff executed responsibilities for corporate governance, quality management,
licensing and accreditation and facility design, commissioning and oversight. Staff were
recruited, trained and managed within separate divisions committed to research and
development, quality control, assurance and cell production. Facilities underwent
design, installation, performance and operational qualiﬁcation. External engagements
included those with institutional and regional advisory committees, UK government
Human Fertilisation and Embryology (HFEA) Authority and Human Tissue Authority
(HTA), Professional Standards (ISO9001) accreditation, suppliers of services and
reagents/materials, repositories (UKSCB) and licensors, professional societies and
forums, and assisted conception units from which embryos were procured from in vitro
fertilisation (IVF) patients, whose patient information and consent (PIC) and embryo
donation were administered by nurse counselors and embryologists not involved in
decisions concerning patient's infertility treatment. Concurrent development of staff,
protocols and facilities coupled with external engagements yielded a capability for GMP
hESC manufacture resulting in banked hESC lines and auditable stem cell line history
ﬁles (SCHF) available for distribution and licensing.
Master production schedule for GMP hESC derivation and banking. Exemplar of a sche-
matic representation of a master production schedule specifying incubator atmosphere,
processing step (expansion or cryopreservation) in relation to passage number (P), vessel
format (IVF petri dish vs 6 well plate), matrix (Cell Start, Invitrogen) or xeno-free feeders
(FX), quality control (QC) sample points (SP), and tests performed (mycoplasma,
endotoxin).
382 P.A. De Sousa et al. / Stem Cell Research 17 (2016) 379–390Within the organisation, key responsibilities of an executive team
composed initially of a chief executive, scientiﬁc and operations ofﬁcers,
included corporate governance (reporting to a board of institutional
stakeholders and observers), application for and renewal of UK regula-
tory licensing (HTA and HFEA, respectively) and professional accredita-
tion (British Assessment Bureau – BA – ISO 9001 certiﬁcation), facility
design and establishment of a Quality Management System. The latter
was founded onQ-Pulse software, adapted for use as guided by partners
at the SNBTSwith prior experience of its application in adult cell and tis-
sue manufacture and therapy. Key internal operational tasks consisted
of: i) recruitment, training and management of staff dedicated to
research and development, quality control (QC), QA and cell produc-
tion; ii) cell manufacturing facility design, installation, operation and
performance qualiﬁcation (DQ, IQ, OQ, PQ); and iii) protocol develop-
ment, qualiﬁcation and implementation in the production facility. Key
external engagements and associated tasks included establishment
andmaintenance of: i) institutional advisory and regional health service
ethics committee approval of information, consent and procedures for
tissue procurement; ii) contractual agreements with collaborators
(assisted conception units), suppliers and service providers andspeciﬁcation of associated technical protocols and schedules; and iii) re-
lationships with professional forums (i.e. UK National Clinical Human
Embryonic Stem Cell Forum), repositories (i.e. UK Stem Cell Bank) and
prospective licensors. Operational speciﬁcations were guided by EU
and US directives and guidance (Tables 1 & 2), with all tasks converging
on realisation of the central aim to establish seed banks of hESC with
documented history ﬁles warranting compliance of this resource to
serve as source material for clinical application (Fig. 1).
Room
Classification
(EU GMP)
Static Pressure
(Pa)
Air Change Rate
(air 
changes/hour)
Entry  
(Change Area 1)
Unclassified 20
Entry Laboratory D 20
Change Area 2 D/C 30 >30
Material Prep. Lab C 40 >30
Change Area 3 C/B 50 >30
GMP Production Lab B 65 >30
Fig. 2. Facility design and environmental speciﬁcation. A purpose built controlled atmosphere facility, approximately 64 m square, was designed, constructed and validated to maintain
ambient atmosphere speciﬁcations compliant with EU GMP speciﬁcations (B–D, unclassiﬁed) in order to derive and cultivate GMP grade hESC, or other human cells. This consisted of
3 laboratory spaces (HESC and Material Preparation and Entry) separated by change areas with step over barriers, and cascading air pressures, diminishing from the heard of the
facility towards the entry from an unclassiﬁed atmosphere of an internal corridor of the institution (Roslin Institution) within which it was located. The air change (AC) rate
throughout the facility was N30 changes/h (h), with a step change in air pressure of approximately 10–15 Pa (pa) per room from 65 to 20. Rooms were minimally equipped with
horizontal and vertical ﬂow cabinets providing an EU GMP grade A speciﬁcation, light microscopes (LM), heated stages, Bench top centrifuges, stacked incubations (hESC preparation),
fridges/freezers and water baths (material preparation), and moveable trolleys holding tracked disposable supplies required at time of cell processing. Materials in/out of the facility
were transferred between labs via transfer hatches with cross-locking doors precluding simultaneous opening from both sides. Operator gowning in each laboratory were as required
to maintain ambient atmospheric speciﬁcations.
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capabilities evolved concurrently (Supplementary Fig. 1). Staff recruit-
ment, training and management commenced in January 2006 with the
focus of recruitment and training shifting from research and develop-
ment of hESC derivation protocols to establishment of QC/QA oversight
and execution of QA cell production, as operational capacity grew and
facilities were constructed. In the ﬁrst instance RC occupied laboratories
and ofﬁce space in Roslin Institute, previously licensed by the HFEA forhESC derivation (No. R0136, centre 202, Dr Paul De Sousa, Person Re-
sponsible). Through 2007/8 we designed, installed and operationally
qualiﬁed a new laboratory facility providing the controlled and graded
environmental speciﬁcation required for GMP cell production. Once
operational this was licensed by the HFEA as well as the HTA (No.
22515, Dr Paul De Sousa, Designated Individual). This facility was ﬁrst
inspected by the HTA in March 2010. Concurrent with establishment
of facilities and operations, hESC derivation and banking protocols
384 P.A. De Sousa et al. / Stem Cell Research 17 (2016) 379–390underwent phases of development, qualiﬁcation and ﬁnally production.
Protocols varying in methodology and constituent reagents were
compared against a reference standard through random allocation of
donated embryos (development). Reagents and suppliers were selected
on the basis of the absence or qualiﬁcation of the provenance of animal
or human sourced components integral to their composition or used in
their production and production standards assessed by questionnaires
and supplier audits. During the qualiﬁcation phase, the efﬁcacy and out-
come of protocols utilising animal-free or animal/human component
qualiﬁed reagents were conﬁrmed. Conﬁrmed protocols were then
translated into a production schedule deﬁned by comprehensive
documentation of the protocol and associated information including;
component reagents, batch records, staff competence, environmental
speciﬁcation, in process and batch release quality control parameters.
2.2. Ethical and quality assured procurement of embryos and donor
screening
HFEA licensure required ethics advisory committee approval of
patient information and consent and procurement procedures. This
was provided by both institution speciﬁc boards (Roslin Institute/Roslin
Cells and private assisted conception units (ACU) – University College
Hospital) and a centralized national health service Research Ethics
Committee (i.e. Scotland A) providing overarching approval for all
supporting ACU, namely University College London, St Mary's Hospital
(London), Aberdeen Fertility Centre, Ninewells Hospital (Dundee), and
Edinburgh Assisted Conception Unit. In accordance with the ﬁrst HTA
and then HFEA licensing ACUs third party agreements deﬁning mutual
responsibilities were established. Embryo donor information and
consent was provided/conﬁrmed by a nurse counselor in accordance
with a StandardOperating Procedure (SOP) for provision of information
and consent and recording of patient information including; acknowl-
edgement of the key terms of consent (Supplementary Fig. 2), donor
screening and medical history information and records of inter-institu-
tional shipment. All donors were screened for the tests required in
Commission Directive 2006/17/EC and conﬁrmed negative for human
immunodeﬁciency virus (HIV-1 & 2), and hepatitis B & C, and if risk
assessed by clinical carers, further tested for human T-cell lymphotropic
virus (HTLVI/II, cytomegalovirus (CMV), Treponema pallidum (syphilis),
Chlamydia trachomatis or Neisseria gonnorhea. During donor
medical history assessment donor risks for transmissable spongiform
encephalopathies, hepatitis and sexually transmitted diseases were
assessed (Supplementary Fig. 3).
All embryo donations were voluntary and consisted of embryos
designated as surplus fresh, surplus frozen and fresh failed for use in in-
fertility treatment as assessed independently by embryologists involved
in treatment. Surplus fresh embryos were morphologically abnormal
and deemed of insufﬁcient quality for freezing. Fresh failed embryos
were a separate category of “fresh surplus” assessed to be delayed in
their developmental progression and also unsuitable for use in infertil-
ity treatment. Over the 5 year period during which embryo donations
were procured, a total of 548 failed, 287 surplus fresh and 270 surplus
frozen embryos were utilized in the development and implementation
of protocols and operational capability (Supplementary Fig. 4).
The chain of custody fromACU to RCwas systematically documented.
Donor identity was traceably anonymised by assignment of a tracking
code. Couriered shipmentswere tracked andmonitored live using online
GPS tracking. The primary tissue was transported in specialised
containers which had been validated for use. Where fresh tissue was
transported the shipment was continually monitored using a calibrated
temperature monitoring device. For frozen tissue being transported
using a dry shipper, the temperature of the vessel was checked upon
receipt as a minimum.Where possible, a dry shipper with a tracking de-
vice was used. All shipping containers were securely locked and labelled
in line with regulatory requirements. Only approved courier services
under third party agreements were used. Upon receipt of the shipmentat RC, there were a number of checks made to ensure that the donated
material fulﬁlled acceptance criteria, deﬁned by RC's quality control
department, independent of the derivation/production process. Checks
included conﬁrmation from the nurse counselor interfacing with the
donors that consent had not been withdrawn, the receipt of pertinent
documentation associated with the donation, and that the shipping
container was intact. Documentation included: i) anonymised patient
information and consent, ii) donor screening (including for blood
borne viruses), iii) donor medical history questionnaire, and iv) a
transfer documentation/checklist prepared at the ACU. Once the dona-
tion was released as acceptable for use, a unique RC tracking number
was assigned to the donation for internal use. Upon receipt by the
production team the shipment was checked to conﬁrm that: i) the
shipping temperature had beenmaintained, ii) the individual containers
are intact, and iii) the numbers of units of donated material received
match the numbers shipped.
2.3. Reﬁnement of hESC derivation and banking protocols
Summary and comprehensive details of embryo and hESC prove-
nance, culture and cryopreservation methods, reagents, environmental
conditions, quality control assessment and characterization for each
hESC line generated in the programme are summarized in Table 3 and
Supplementary Figs. 1, 3, & 5, with further detail elaborated in corre-
sponding Lab Resource publications (De Sousa et al., 2016a, 2016b,
2016c, 2016d, 2016e, 2016f, 2016g, 2016h, 2016i, 2016j, 2016k, 2016l,
2016m, 2016n, 2016o, 2016p, 2016q). History ﬁles for each line are
available for inspection under conﬁdential agreement. Vitriﬁed embry-
os were thawed using Vitriﬁed Embryo Safety Thawing Pack (Kitazato,
Valencia, Spain) according to the manufacturer's instruction. Frozen
embryos were thawed using Embryo Thawing Pack (Medicult, Måløv,
Denmark) or Sydney IVF/Blastocyst Thawing Kit (Cook Medical,
Bloomington, Indiana, USA) using standard techniques. Fresh or thawed
embryos received prior to day 3 post fertilization were cultured in
Sydney cleavage medium (Cook Medical), SAGE Quinn's Advantage
Cleavagemedium(Origio,Måløv, Denmark; formerly Rochford Biomed-
ical), or EmbryoAssist (Medicult). On day 3 of development, or for
embryos received or thawed after this stage, embryos were transferred
to blastocyst medium for the appropriate culture system (SAGE Quinn's
Advantage Blastocyst medium (Origio), Sydney blastocyst medium
(Cook Medical) or BlastAssist (Medicult)). Embryos were cultured at
36.5–37.5 °C, 5 ± 0.5% CO2, 5 ± 0.5% O2 in drops under parafﬁn oil
and transferred to fresh medium at least every 2–3 days. HESC deriva-
tion was initiated by whole embryo outgrowth on a supportive
substrate. In the course of the programme, protocols transitioned from
commencing outgrowth at 6 days post fertilization to 8 days.
The initial reference standard conditions for hESC derivation against
which improvements in the protocol were compared consisted of a
substrate of mitotically inactivated (by γ-irradiation) non-GMP grade
human neonatal foreskin ﬁbroblast feeders (HDF) (RCM1, RC2-8) on
plasticware pre-coated with human laminin (RCM1, RC2, 3, 5–6). An
extracellular matrix cocktail consisting of separately sourced human
laminin, vitronectin, ﬁbronectin and collagen IV (Ludwig et al., 2006)
was used successfully to derive RC-4, but batch variation and limited
supply of these reagents constrained commitment to this approach.
Subsequently, it was found that pre-coating of culture vessels with
laminin was superﬂuous for derivation and this was removed from
the process from RC-7 onwards. Quality Assured GMP grade HDF
approved by the US FDA for human application was licensed from
Forticell Biosciences (Englewood, New Jersey, USA) and used in all
subsequent derivations (RC9–17). These were cultured in medium
containing pharmaceutical grade fetal bovine serum prior to mitotic
inactivation (by γ-irradiation). Reference standard medium consisted
of HDF conditioned Knock-Out Dulbecco Minimal Essential Medium
(KO-DMEM) supplemented with knockout serum replacement
(KOSR), 24 ng/ml bFGF and additional chemical nutrient supplements
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385P.A. De Sousa et al. / Stem Cell Research 17 (2016) 379–390(Fletcher et al., 2006). The KOSRwas ultimately replacedwith xeno-free
serum replacement and the concentration of bFGF was elevated to
80 ng/ml bFGF. For HESC expansion and banking, a feeder free system
was adopted consisting of Cellstart matrix and Stempro Serum Free
Medium (ThermoFisher Scientiﬁc, Waltham, Massachusetts, USA).
Although most of the reagents selected for use were not formally
manufactured to GMP standards, all reagents were reviewed and ap-
proved by QA as suitable for use in a GMP process. Throughout the pro-
cess, cell passaging was performed mechanically by manual dissection
using an EZ passage tool (ThermoFisher Scientiﬁc). Cryopreservation
of hESC to establish seed banks evolved from initial use of KOSR and
DMSO as cryoprotectants and unmonitored controlled rate freezing
achieved by a ‘Mr Frosty’ isopropanol tub placed at -80 °C for 24 h to
use of a GMP grade cryoprotectant (Cryostor CS10; Stemcell Technolo-
gies, Vancouver, Canada) and temperature monitored controlled rate
freezing using the liquid nitrogen free controlled rate freezer EF600-
107 (Grant Instruments, Cambridgeshire, UK) operated in an environ-
mentally monitored GMP cell production facility.
2.4. Cell manufacturing environment
The GMP cell production facility was designed to comply with
EU Good Manufacturing Practice Guidelines (Eudralex Volume 4),
speciﬁcally for manufacture of sterile biological active substances and
medicinal products for human use (Eudralex vol 4, Annexes 1 & 2). A
comprehensive Site Master File has been compiled describing the
establishment and operation of the RC facility in the course of the
programme, and this is available for inspection under conﬁdentiality
agreement. The facility was designed to operate in compliance with EC
Guide to GMP annex 1, with appropriate cleanroom design and
standards of operation and monitoring. Key features of operation in-
cluded regular monitoring of the facility for air temperature, humidity
and pressure, and for particle and microbiological counts. Operational
features included careful design of the ﬂow of rawmaterials, personnel
and waste, with requisite garment change areas and cross-overs. The
layout and environmental speciﬁcation of the facility are provided in
Fig. 2. All open processing was carried out within Grade A class II safety
cabinets. All hESC lines have been stored in dedicated vapour phase liq-
uid nitrogen or mechanical freezers maintained at−150 °C ± 10 °C.
These were originally at Roslin Institute and subsequently moved to
the new Scottish Centre for Regenerative Medicine facility. Lines are
also stored in sub-contracted off-site storage, and at the UK Stem Cell
Bank (UKSCB).Mechanical freezers also feature a liquid nitrogen backup
system which could deploy vapour phase liquid nitrogen to the freezer
in case of mechanical failure. The ambient temperature of the storage
facility is monitored to ensure that equipment is maintained as per
manufacturer's recommendations.
2.5. The manufacturing process
GMP grade culture of embryos and derivation of hESC deﬁned in
productionmaster schedules (PMSs). These documents provide process
overviews and include references to all SOPs, production batch records,
rawmaterials, equipment and consumables required. All rawmaterials
were quarantined upon receipt until inspected by RC's QC department
to ensure that only approved products, meeting the speciﬁcation were
used in production processes. Following procurement and culture of
embryos to the blastocyst stage, zona pellucida coveringswere removed
mechanically if embryos had not already escaped this covering, and
embryos were allowed to attach to growth substrates provided.
Successful outgrowths were nurtured to form hESC colonies which
were cultured until a hESC line was established. For each hESC line a
seed lot of vials was cryopreserved, from which subsequent banks
have been established by thawing and further expansion. Processes
were appropriately segregated to minimise the risk of cross contamina-
tion. Segregation was applied to processes at different levels including
386 P.A. De Sousa et al. / Stem Cell Research 17 (2016) 379–390the processing of donations of embryos fromdifferent donors andwhen
processing of different cell lines. Appropriate ‘line-clearance’
procedures were employed between processes. All processing steps
were documented in SOPs and activitieswere recorded in batch records.
These batch records were controlled and issued by RC's QA department.
All completed records were subject to a QC check and QA audit.
Documentation provided traceability of all reagents, consumables and
personnel involved with all processing steps.
Through-out the programme Roslin Cells sought to use raw mate-
rials suitable for GMP compliant manufacturing. The ideal source ofma-
terials are those in either of the 3 categories, i.e. licensed pharmaceutical
products (such as human albumin), pharmacopoeial grade reagents
(such as EP grade acids) or speciﬁc reagents which are manufactured
toGMPgrade. GMPgrade reagents are relatively rare for use in theman-
ufacture of cellular therapies. Where such GMP-compliant materials
could not be sourced then a risk based approach was taken to assess
the manufacturer, the manufacturing process and the product itself to
make an informed decision on whether or not it could be used. Where
possible we strived to avoid the use of products containing animal
derived components with chemically deﬁned products used as much
as possible if proven to be efﬁcacious. If animal derived products were
used, then a TSE evaluation was carried out using the methodology de-
ﬁned in the current version of the EMA note for Guidance (EMEA/410/
01). All equipment used in manufacturing was procured, validated
and maintained to meet GMP requirements for the entire life cycle of
the item. Equipmentwork ﬁles are still retained capturing a documented
history for each item of equipment.
2.6. Quality control
RC established and maintains a QC department independent of pro-
duction. Amongst other activities QC is concerned with inspection of
raw materials, speciﬁcations and testing, maintenance of reference
and archive samples of product, labeling of containers of ﬁnal product,
environmental monitoring and testing of operator aseptic technique.
Training and testing of operator aseptic technique encompass gowning
aswell as technical procedures. Environmentalmonitoringwas restrict-
ed to environmentally classiﬁed spaces of the cell manufacturing at set
intervals (i.e. pre and post cleaning activities) and at the time of cell
processing.
2.7. Quality control testing of hESC lines
A deﬁned regime of quality control (QC) testing was been
established for both in process assessment, batch release and additional
information for hESC lines produced gathered in Certiﬁcates of Analysis
(Supplementary Fig. 6, and provided in De Sousa et al., 2016e, 2016f,
2016g, 2016h, 2016i, 2016j, 2016k, 2016d for RC9, 11–17, respectively).
All QC testing was performed using validated equipment by trained
staff working to SOPs for each technique and recording of data. All
outsourced assays were associated with formal agreements with
accredited service providers.
2.7.1. Mycoplasma
Mycoplasma detection was performed using Applied Biosystems
PrepSEQ™ Mycoplasma Nucleic Acid Extraction Kit and MicroSEQ™
Mycoplasma Real-Time PCR Detection Kit (Applied Biosystems, Foster
City, California, USA) according to the manufacturer's instruction.
Brieﬂy, cells were lysed and DNA isolated from the culture using a
magnetic bead-based method. The puriﬁed DNA template was mixed
with assay mix and Power SYBR© green master mix and run on the
RT-qPCRmachine. For an assay to be considered valid the discriminato-
ry positive and extraction positive control must be “detected” and the
PCR negative control and extraction negative control must be “not
detected”. Mycoplasma was considered detected in a sample if the
cycle threshold value (Ct) was less than 35.00, the target Tm valuewas between 75° and 85 °C and the Tm derivative value was greater
than or equal to 0.05.
2.7.2. Endotoxin
Endotoxin levels were determined using the Kinetic-QCL assay
(Lonza, Basel, Switzerland) and an incubating plate reader (BioTek
ELx808; Winooski, Vermont, USA) according to the manufacturer's
instructions. Brieﬂy, an unknown sample was compared with a stan-
dard curve of known levels of control endotoxin. An assay was deemed
valid if the coefﬁcient of correlation, r ≥ 0.980 and the CV (%) for the
standard curve was ≤10%.
2.7.3. Viability
Viability was determined using the Guava ViaCount assay. Brieﬂy,
the Guava Viacount reagent (Millipore, Billerica, Massachusetts, USA)
containing a nuclear and a viability dye, was mixed with a single cell
suspension, incubated for 5min and analysed using the Guava easyCyte
ﬂow cytometer (Millipore). Total cell count, viable cell count and
percentage viable cells were obtained.
2.7.4. Flow cytometry
A pluripotent phenotype was determined using the Human and
Mouse pluripotent Stem Cell Analysis kit (Becton Dickinson - BD, Frank-
lin Lakes, New Jersey, USA) according to the manufacturer's instruc-
tions. Oct 3/4 and SSEA-4 were included as pluripotency markers, and
SSEA-1 as a differentiation marker. FITC conjugated Tra-1-60 (BD) was
used as an additional pluripotency marker. Fixed and permeabilised
cells were stained with the markers listed above and analysed using
the Guava easyCyte ﬂow cytometer (Millipore). Percentage expression
of each marker was compared to isotype control or unstained cells.
2.7.5. Immunocytochemistry
Immunocytochemical staining was used to provide qualitative
information on cell identity. hESCs were ﬁxed using 4% paraformalde-
hyde (Alfa Aesar, Haverhill, Massachusetts, USA) for 20 min and
permeabilised using 100% ethanol (Fisher Scientiﬁc) for 2 min. Non-
speciﬁc staining was blocked using 10% donkey, goat or rabbit serum
(Sigma Aldrich, St Louis, Missouri, USA) in PBS (Lonza) containing
0.01% Tween-20 (Sigma) for 1 h at room temperature. Primary and sec-
ondary antibodies at optimized dilutions were prepared in a 1% serum
solution in PBS containing 0.01% Tween-20 for 2 h at room temperature
or overnight at 4 °C, with unbound antibody removed by 3 × 5- to 10-
min washes in PBS at room temperature. Slides were mounted in
Vectashield containing DAPI (Vector Laboratories, Peterborough, UK)
and stored at 4 °C in the dark prior to being viewed on a Zeiss S100
Axiovert ﬂuorescence microscope or Nikon eC1 confocal microscope.
Antibody probes consisted of those speciﬁc for AFP (1:500 mouse
monoclonal IgG2a;Sigma), β-tubulin III (1:1000 mouse monoclonal
IgG2b; Sigma), muscle-speciﬁc actin (1:50 mouse monoclonal IgG1κ;
DAKO), Oct-4 (1:200 mouse monoclonal IgG2b; Santa Cruz Biotechnol-
ogy, Dallas, Texas, USA), Nanog (1:20 goat polyclonal; R&D Systems,
Minneapolis, Minnesota, USA ), Tra-1-60-FITC (BD), Tra-1-81-FITC
(BD), SSEA-4 (BD) (all BD sourced antibodies used at concentrations
used by suppliers), Sox 2, anti-mouse IgG (1:200 goat polyclonal IgG-
FITC; Sigma), anti mouse IgG (1:200, goat polyclonal Alexa Fluor 488
ThermoFisher Scientiﬁc), anti-goat IgG (1:200 rabbit AlexaFluor-488;
ThermoFisher Scientiﬁc) and anti-goat IgG (1:200 donkey polyclonal
AlexaFluor-594).
2.7.6. In vitro differentiation
Embryoid body mediated hESC differentiation was induced by pre-
treating near conﬂuent hESC cells with 10 μM ROCK inhibitor in
Stempro hESC SFM (ThermoFisher Scientiﬁc) for 1 h prior to using an
EZ Passage tool (ThermoFisher Scientiﬁc) to generate even sized cell
fragments. These were transferred to ultra low attachment plates
(Corning Inc, Corning, NewYork, USA) and cultured for 7 days, replacing
387P.A. De Sousa et al. / Stem Cell Research 17 (2016) 379–390medium every 2–3 days. The resulting embryoid bodies were trans-
ferred into embryoid body differentiation (EBD) medium consisting of
80% KO-DMEM (ThermoFisher Scientiﬁc), 20% FBS (PAA Laboratories,
Pasching, Austria), 1 mM L-glutamine, 0.1 mM β-mercaptoethanol, 1%
nonessential amino acids (all ThermoFisher Scientiﬁc), plated onto
glass slide tissue culture chambers (Nunc, Rochester New York, USA)
coated with 0.5 % gelatin at 0.1 ml/cm2, and cultured for an additional
of 14 days, feeding every second day, before being ﬁxed and stained.
2.7.7. In vivo differentiation
Information on the developmental potential of RCM-1, RC-9 and RC-
11 to form teratomas consisting of tissues representative of all three
germ layers was evaluated following transplantation under kidney
capsule in adult SCID mice (RCM-1) or NOD scid gamma mice (RC-9
and RC-11). After eight weeks to threemonths, the animals were culled
and assessed for teratoma formation. Teratomas were ﬁxed in 4%
paraformaldehyde, embedded in parafﬁn wax and serial sections of
7 μm thicknesswere cut according to standard procedures. For histolog-
ical assessment, the tissue sections were dewaxed, rehydrated, stained
with haematoxylin and eosin or Masson staining and mounted in
DePex mounting medium. To further conﬁrm the teratoma contained
tissues derived from the three germ layers, dewaxed andhydrated serial
sections were stained with Safranin O and the background stained with
0.02% aqueous Fast Green FCF. Tissue sections were analysed using
bright ﬁeld and microscopy and digital images were recorded.
2.8. External assays
All outsourced assayswere carried out under a Quality and Technical
Agreement. DNA was extracted using the QIAamp DNA Mini kit
(Qiagen, Manchester, UK) according to the manufacturer's recommen-
dations and provided in recommended quantities to the service
providers. Microsatellite PCR, or Short Tandem Repeat analysis, was
used to determine cell line identity andwas carried out by Public Health
England. A proﬁle was obtained for the following core alleles: vWA,
D16S539, Amelogenin, THO1, CSF1PO, D5S818, D75820, D135317 and
TPOX. Human Leukocyte Antigen (HLA) tissue typing was carried out
by the Scottish National Blood Transfusion Service. Blood group
genotyping was carried out by the Molecular Diagnostics laboratory at
NHSBT. Karyotype analysis was carried out by The Doctors Laboratory
or Western General Cytogenetics Laboratory (Edinburgh, Scotland).
Live cells at 60–70% conﬂuency were shipped in warm containers,
ﬁxed and analysed by standard G-banding analysis. For research grade
lines, 20 spreads were analysed whereas for clinical grade lines, 30
spreads were analysed. Viral screening for cytomegalovirus (CMV),
human T-cell lymphotropic virus (HTLV)-1, human immunodeﬁciency
virus (HIV)-1, hepatitis C virus (HCV), hepatitis B virus (HBV) and
Epstein-Barr virus (EBV) was carried out by The Doctors Laboratory
(London, UK). European pharmacopoeia (EP) sterility testing was
carried out by Moredun Scientiﬁc Ltd. (Penicuik, Scotland) using the
culture method.
2.9. SNP genotyping and analysis
DNA samples were assayed using the Illumina HumanCytoSNP-12
v2.1 BeadChip. Genotyping data was initially assessed using
GenomeStudio genotyping module (v1.94, Illumina). Karyostudio
(v1.4, Illumina) was employed to perform automatic normalisation
and to identify genomic aberrations utilising default settings of the
built-in cnvPartition algorithm (3.07, Illumina) to generate B-allele
frequency and smoothened Log R ratio plots for detected regions.
These parameters are designed to detect CNVs greater than 75 kb and
CN-LOH regions larger than 1 MB with a conﬁdence value greater than
35. All identiﬁed regions were ﬁrst cross-matched to the Database of
Genomic Variants (DGV; http://dgv.tcag.ca) to identify naturally-occur-
ring structural variations in human. CNVs that were not identiﬁed onthe DGV were then checked against a list of ES cell-associated culture
adaptation genomic variants published by the International Stem Cell
Initiative (ISCI, Amps et al., 2011). See also Canham et al. (2015) for
further details.
2.10. Quality assurance
Key reference documents informing quality assurance speciﬁcations
included: i) The Rules Governing Medicinal Products in the European
Union (Eurdralex) Volume IV, Good Manufacturing Practice (GMP)
Guidelines; ii) UK Human Tissue (Quality and Safety for Human Appli-
cation) Regulations 2007, iii) EU Tissues and Cells Directive (2004/23/
EC) and related Commission Directives (2006/17/EC, 2006/23/EC and
2006/86/EC), iv) EU ATMP regulations (Regulation 1394/2007), and v)
requirements for ISO 9001:2008 accreditation. A key element of a
GMP compliant operation is the operation and maintenance of an
effective Quality Management System (QMS). An effective QMS pro-
vides for controlled and authorised release of documentation which is
periodically reviewed to adapt and meet the changing demands of the
organisation and cell manufacturing processes. Signiﬁcant features of
the documentation system operated by RC include:
• Quality Audit Programme.
• Systems for recording follow-up and corrective action necessary
when departures from authorised methods occur
• System for reporting and investigating defects and incidents.
• Quality risk management system for identifying and assessing poten-
tial hazards to minimise risk to patients, donors and the organisation.
• Risk assessment procedure used independently for decision making
and planning and as part of other key QMS procedures.
• Training policy for all staff members including the principles, theory
and practice of GMP.
• System for approving and releasing key materials.
• System for the compilation of batch documentation for ATMP
products.
• System for validation of equipment (including IT systems), processes
and QC methods.
• Change control system.
• System for product recall
3. Results
The overarching goals of the Roslin Cells programme were the
development and implementation of quality assured operational
management and construction of a GMP grade cell manufacturing
facility centred on establishment of GMP compliant hESC derivation,
expansion, cryopreservation and banking. In order to demonstrate
compliance with appropriate standards, the facility was operated
under ISO9001:2008 standards and licensure from the UK HFEA and
HTA. In order to comply with these standards, it was necessary to
compile a systematic and traceable documentation of all elements of
operation from receipt of embryos until deposition of cell lines. In accor-
dance with the concurrent development of governance and facility
infrastructure, licensure, and methodology we consider that of the 17
hESC lines derived in the programme (Table 3), RC-9, 11–17 were
derived to a quality assurance standard appropriate for their use as
source material for clinical application. The essential attributes of
these lines includes:
• A fully traceable procurement and processing
• Ethical consent, including provision for commercial use
• Detailed medical history and blood borne virus (BBV) screening of
donors
• A compilation of detailed cell line history
• Clearly detailed hESC manufacturing process
• A quality control testing regime.
• A mature Quality Management System, including:
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ongoing licensing approval.
o Provision of regular reports on the performance of the QMS and
executive review.
o Appropriate staff were in place, with effective line management,
training and development.
o Facility design, installation and operational qualiﬁcation andmainte-
nance within regulatory deﬁned speciﬁcations.
o Equipment procurement, performance and maintenance
o Effective research and development to optimise the manufacturing
procedures.
o Risk assessment and adverse event response tracking.
o Segregation of research and development, production, quality
control and quality assurance operational practice.
o Third party agreements assisted conception units and service
suppliers.
4. Discussion
We describe here the development and implementation of an
operation and facility in the form of a not-for-proﬁt company, Roslin
Cells Ltd, for the speciﬁc purpose of manufacturing clinical grade hESC
lines for use in regenerative medicine. This yielded 17 hESC lines of
which 8 lines (RC9, 11–17; De Sousa et al., 2016e, 2016f, 2016g,
2016h, 2016i, 2016j, 2016k, 2016d) are compliant with European
Union (EU) directives and United Kingdom (UK) licensure for procure-
ment, processing and storage of quality assured human cells as source
material for clinical application. The production of these lines was
targeted to comply with EU GMP speciﬁcations as can be conﬁrmed
through inspection of associated cell line history ﬁles and QMS
controlled documentation.
The key issue for further use of these cell lines is whether or not they
comply with the requirements for further processing of an ATMP. In the
EU, the requirements for accepting onward processing of a master cell
bank rest with an assessment with the degree of compliance with
GMP. Guidance on this topic is available in a reﬂection paper on stem
cell-based medicinal products prepared by the European Medicines
Agency (EMA/CAT/571134/2009), where the key requirements for cell
lines used as starting materials for medicinal products are all laid out.
In addition, Annex 2 of the EC Guide to GMP provides an illustrative
guide as to the level of GMP required for different stages in the prepara-
tion of a medicinal product. In this guide, donation, procurement and
testing of starting tissues/cells require to have been carried out in com-
pliancewithDirective 2004/23/EC (TissueDirective). Subsequent stages
of manufacture of a clinical product require to be carried out under
GMP. However, the guidance in Annex 2 makes it clear that the level
of GMP adherence will increase at each stage from isolation, through
MCB, WCB and towards the ﬁnal product.
Our efforts were targeted to comply with an EU GMP grade speciﬁ-
cation. However, at the time of establishing seed banks, a site license
from the UKMHRA for the manufacture of biologics for human applica-
tion had not yet been obtained. Thus, the extent to which the lines
satisfy EU GMP speciﬁcations requires retrospective inspection of cell
line history ﬁles and archived QMS controlled records. Based on our
understanding of EU (Table 1) directives, guidance and regulations
associated with procurement, processing, non-clinical studies, and
manufacture, we believe that the lines exceed speciﬁcations to serve
as source material in the EU. A second generation facility established
at the University of Edinburgh Scottish Centre for Regenerative
Medicine has subsequently been licensed by the MHRA and the lines
continue to be stored in an MHRA licensed facility. It is known that
clinical trial authorisations have been granted for the manufacture of
clinical products derived from cell lines which were prepared in
facilities which were not operating to GMP standards. Although our
ﬁrst facility, in which hESC lines were derived, was not licensed by the
MHRA at the time that the cell lines were manufactured, we believethat the data available would support future clinical trials and subse-
quent licensure of products derived from these cell lines.
Our facility was not licensed by the US FDA for the manufacture of
biologics to US guidelines standards for current Good Tissue Practice.
However, our interpretation of these guidelines and standards
(Table 2) is that they do not differ substantially from the requirements
of EC directives and of HFEA and HTA licensure. There are some differ-
ences between EU and US in terms of administration and speciﬁcation
of GMP. Technical speciﬁcations can also vary, such as for ambient
environment classiﬁcation (i.e. comparison of Eudralex Vol 4, Annex I
vs FDA Aseptic processing guide for GMP). However, irrespective of
such nuances, either standard provides the highest level of traceability,
control and quality assurance, and aspiring to comply with either can
provide a higher level of assurance of source material than otherwise
is mandated by both jurisdictions currently. It is our understanding
based on the analysis in Table 2 that the cell lines prepared at Roslin
Cells will be suitable for onward processing in the USA. However, this
will require to be tested by consultation and discussion with the US
FDA. Lastly, guidelines prepared by the International Society for Stem
Cell Research (ISSCR) (2006, 2008, 2016) for global standards of con-
duct of Human Embryonic Stem Cell Research and clinical translation
originally published in 2006 and 2008 (respectively) were recently
updated (see Commentary, Daley et al., 2016). Our review of these
conﬁrms compliance of all hESC lines created in our programme with
applicable standards (Supplementary Fig. 7).
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